Trial Profile
Phase II study of capecitabine in combination with oxaliplatin and radiotherapy for esophageal and gastroesophageal junction cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Capecitabine (Primary) ; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 18 Sep 2012 Planned End Date changed from 1 Apr 2010 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 09 Mar 2011 Planned end date changed from 1 Sep 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.